CDMO Daily News — August 6, 2026

AsymBio Secures $184M to Expand Biologics Manufacturing and GMP Capacity

• AsymBio raised 1.2397 billion yuan ($184M) from Asymchem Group, Hillhouse Qirui, and others to fund manufacturing expansion, GMP lines, and high-containment facilities.
• Asymchem Group's stake in AsymBio will increase to 83.5% post-closing, reinforcing the parent's end-to-end CDMO and contract manufacturing strategy.
• AsymBio reported 2025 revenue of 470M yuan and Q1 2026 revenue exceeding 140M yuan, with capabilities spanning early-stage development through commercial manufacturing and ADC production.

Operational Impact

AsymBio's $184M capacity expansion and new GMP lines increase available biologics manufacturing slots in the Asymchem ecosystem, particularly for ADC and protein therapeutics programs seeking clinical-to-commercial scale-up.

Source: PharmaSource RSS

CordenPharma Completes AmbioPharm Acquisition, Adds U.S. and Asia Peptide Capacity

• CordenPharma acquired peptide CDMO AmbioPharm, integrating facilities in North Augusta, South Carolina and Shanghai, China into its manufacturing network.
• South Carolina site expands downstream capabilities (purification, lyophilization); Shanghai adds upstream peptide manufacturing capacity.
• Combined network reaches ~3,500 employees and now spans North America, Europe, and Asia with peptide APIs, sterile injectables, and oral solid dosage capabilities.

Operational Impact

CordenPharma's integration of AmbioPharm's South Carolina and Shanghai facilities adds dedicated peptide upstream and downstream capacity across two continents, reducing single-geography risk for peptide programs in development and commercial phases.

Source: PharmaSource RSS

Altasciences Expands Harleysville R&D Lab with Integrated Formulation and Analytical Testing

• Altasciences added 768 sq ft of R&D laboratory space at its Harleysville, Pennsylvania drug-product formulation and manufacturing facility.
• The integrated lab combines formulation development and analytical testing to accelerate early-stage drug development for small molecules, peptides, and complex modalities.
• The expansion includes scientific team growth and supports non-GLP and GLP toxicology sample preparation for nonclinical studies.

Operational Impact

Altasciences' Harleysville expansion strengthens early-stage CDMO capabilities and reduces formulation-to-clinic timelines by co-locating development and testing, allowing clients to optimize products before regulated studies.

Source: PharmaSource RSS

Piramal Pharma Solutions Opens Spray-Drying Suite for Peptide Formulation in India

• Piramal Pharma Solutions commissioned a spray-drying suite at its Turbhe, India facility to support peptide and complex-molecule formulation development and manufacturing.
• The closed-loop system handles potent compounds up to Band 5 containment, maintains ISO Class 8 cleanliness, and processes feed rates up to 1 L/h for high-potency, small-volume batches.
• The investment addresses peptide formulation challenges including stability, bioavailability, and scale-up, expanding Piramal's CDMO capabilities across multiple therapeutic areas.

Operational Impact

Piramal's new spray-drying suite at Turbhe expands its peptide CDMO capacity in India, enabling formulation support for high-potency batches and potentially attracting sponsors seeking potent-compound handling expertise in APAC.

Source: PharmaSource RSS

Taysha Secures Commercial Manufacturing with Catalent for Gene Therapy TSHA-102

• Taysha Gene Therapies expanded its partnership with Catalent to a commercial supply agreement for TSHA-102, an investigational AAV gene therapy for Rett syndrome.
• Catalent will serve as primary commercial manufacturer from its FDA-licensed gene therapy facility in Harmans, Maryland, following potential FDA approval.
• BLA-enabling Process Performance Qualification activities are underway; the agreement provides long-term capacity and scalable supply framework for commercial launch.

Operational Impact

Catalent's Harmans gene-therapy facility gains a commercial-stage AAV program, adding to its 90+ gene therapy programs and demonstrating continued capacity utilization in rare-disease manufacturing.

Source: PharmaSource RSS

References

1. PharmaSource RSS — AsymBio Secures $184M to Expand Biologics Manufacturing and GMP Capacity
2. PharmaSource RSS — CordenPharma Completes AmbioPharm Acquisition, Adds U.S. and Asia Peptide Capacity
3. PharmaSource RSS — Altasciences Expands Harleysville R&D Lab with Integrated Formulation and Analytical Testing
4. PharmaSource RSS — Piramal Pharma Solutions Opens Spray-Drying Suite for Peptide Formulation in India
5. PharmaSource RSS — Taysha Secures Commercial Manufacturing with Catalent for Gene Therapy TSHA-102